Medical Advocates

Emtricitabine(Emtriva)
 
Journal Citations

General Reports
Diagnostics
Resistance
Pharmacokinetic
Efficacy
Adverse Events
Therapeutic Strategies


 

 

Emtricitabine Main Page Main New/Newsworthy  Home Page      

Last Update:  March 18, 2017  
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       

 
Amino Acid Esters Substituted Phosphorylated Emtricitabine and Didanosine Derivatives as Antiviral and Anticancer Agents.
Sekhar KC, Janardhan A, Kumar YN, et al

Appl Biochem Biotechnol
.
2014 May 2
Abstract

Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Khatri A, Dutta S, Dunbar M, et al
Antimicrob Agents Chemother
. 2016 Apr 22;60(5):2965-71.
Abstract

The E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine as indicated by competitive fitness assays
Sluis-Cremer N, Huber KD, Brumme CJ, Harrigan PR.
Antimicrob Agents Chemother. 2014 Jan 13
Abstract

FULL-TEXT ARTICLE

Low Level Determinations of Methyl Methanesulfonate and Ethyl Methanesulfonate Impurities in
Emtricitabine Active Pharmaceutical Ingredient by LC/MS/MS Using Electrospray Ionization.
Kakadiya PR, Chandrashekhar TG, Ganguly S,  et al
Anal Chem Insights. 2011;6:21-8.
Paper

The antiretroviral potency of emtricitabine is approximately 3-fold higher compared
to lamivudine in dual human immunodeficiency virus type 1 infection/competition

experiments in vitro.
Drogan D, Rauch P, Hoffmann D,  ET AL

Antiviral Res
. 2010 Jun;86(3):312-5

Abstract

Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
[No authors listed] 
Prescrire Int
. 2005 Apr;14(76):54-6.
Abstract
 

Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its
Once Daily Dosing for the Treatment of HIV Infection.
Wang LH, Begley J, St Claire RL, et al  

AIDS Res Hum Retroviruses.
2004 Nov;20(11):1173-82.
Abstract
 
Emtricitabine: A Once-Daily Nucleoside Reverse Transcriptase Inhibitor (CE) (June).
Modrzejewski KA, Herman RA.
 
Ann Pharmacother.
2004 Apr 30
Abstract
 
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.
Cahn P.
Expert Opin Investig Drugs. 2004 Jan;13(1):55-68.
Abstract
 
Polysaccharide-based chiral phase under polar organic mode of elution in the
determination of the enantiomeric purity of emtricitabine an anti-HIV analogue nucleoside.

Cass QB, Watanabe CS, Rabi JA   

J Pharm Biomed Anal. 2003 Nov 24;33(4):581-587
Abstract

Emtricitabine: 524W91, BW524W91, Coviracil, FTC.
Drugs R D 2003;4(1):42-48
Abstract

 

Pharmacokinetics
       

 
Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men: results from EVARIST ANRS-EP 49 study.
Valade E, Tréluyer JM, Illamola SM,  et al
 
Antimicrob Agents Chemother
. 2015 Aug 17.
Abstract

Pharmacokinetics of Single- and Multiple-Dose Emtricitabine in Healthy Male Chinese Volunteers.
Han WL, Shang JC, Yan B, et al

Pharmacology
. 2014 May 1;93(3-4):166-171
Abstract

Population Pharmacokinetics of Emtricitabine in HIV-1-infected Adult Patients.
Valade E, Tréluyer JM, Bouazza N,  et al
Antimicrob Agents Chemother. 2014 Feb 3.
Abstract

Pharmacokinetic Evaluation of Emtricitabine in Combination With Other Nucleoside
Antivirals in Healthy Volunteers.
Zong J, Chittick GE, Wang LH, et al 

J Clin Pharmacol
. 2007 May 25;
Abstract
 

Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support
Its Once Daily Dosing for the Treatment of HIV Infection.
Wang LH, Begley J, St Claire RL, et al  

AIDS Res Hum Retroviruses.
2004 Nov;20(11):1173-82.
Abstract

Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily
for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091
trial).
Molina JM, Peytavin G, Perusat S, et al  

HIV Med. 2004 Mar;5(2):99-104.
Abstract

Diagnostics
       

 
An Investigation of Liquid Chromatography-Mass Spectral Attributes and Analytical Performance Characteristics of Tenofovir, Emtricitabine and Efavirenz in Human Plasma.
Ndolo SM, Sichilongo K, Massele A,  et al
J Anal Toxicol.
2015 Oct 20.
Abstract

Use of Micellar Liquid Chromatography to Analyze Darunavir, Ritonavir, Emtricitabine, and Tenofovir in Plasma
Peris-Vicente J, Villarreal-Traver M, Casas-Breva I,  et al
J Sep Sci
. 2014 Aug 7.
Abstract

Selective Determination of Antiretroviral Agents Tenofovir, Emtricitabine, and Lamivudine in Human Plasma
by a LC-MS-MS Method for a Bioequivalence Study in Healthy Indian Subjects.
Yadav M, Singhal P, Goswami S, et al
 J Chromatogr Sci
. 2010;48(9):704-13.
Abstract

A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations
of tenofovir and emtricitabine in HIV infected patients.
D'Avolio A, Sciandra M, Siccardi M, et al
  
J Chromatogr Sci.
2008 Jul;46(6):524-8.

Abstract


Resistance
       

 
Do resistance patterns vary between different FTC containing drug regimens?
Chacko L.
J Infect. 2014 Feb 7.
Abstract

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1.
Heredia A, Davis C, Amin MN, Le NM,  et al
AIDS. 2013 Dec 10.
Abstract

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A,  et al
J Antimicrob Chemother
. 2013 Jan 29.
Abstract

Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use
Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz.
McColl DJ, Margot N, Chen SS,  et al
HIV Clin Trials
. 2011 Mar-Apr;12(2):61-70
Abstract

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Borroto-Esoda K, Parkin N, Miller MD.
Antivir Chem Chemother. 2007;18(5):297-300.
Abstract
 

Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine
Susceptibility.

Ross LL, Parkin N, Gerondelis P, et al 
J Acquir Immune Defic Syndr. 2006 Oct 30;
Abstract

Efficacy
       

HBV  Indications
 
 
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with
decompensated chronic hepatitis B liver disease.
L
iaw YF, Sheen IS, Lee CM,   et al
Hepatology
. 2011 Jan;53(1):62-72.
Abstract

Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B Virus.
Saag MS.

Clin Infect Dis. 2
006 Jan 1;42(1):126-31.
Abstract

Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV
trials of emtricitabine.
Mondou E, Sorbel J, Anderson J  
Clin Infect Dis. 2005 Sep 1;41(5):e45-7.
Paper

HIV  Indications
 

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.
Post FA, Yazdanpanah Y, Schembri G, et al
HIV Clin Trials. 2017 Mar 17:1-6.
Abstract

Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Corado KC, Daar ES.

Expert Opin Pharmacother
. 2017 Feb 2.
Abstract

Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.
Gordon LL, Gharibian D, Chong K, Chun H.
AIDS Patient Care
STDS
. 2015 Jul;29(7):384-388.
Abstract


Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Anderson PL, Kiser JJ, Gardner EM, et al
J Antimicrob Chemother
. 2010 Nov 30.
Abstract

Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological
improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Lafaurie M, Collin F, Bentata M, et al  
J Antimicrob Chemother. 2008 Jul 28.
Abstract
 

Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking
highly active antiretroviral therapy.
Marconi P, Lorenzini P, Borrelli I, et al 
New Microbiol. 2006 Jul;29(3):169-75.
Abstract
 
Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in
HIV-1-Infected Adults with Viral Suppression Receiving a Protease Inhibitor-Based
Regimen: A Randomized Trial.
Molina JM, Journot V, Morand-Joubert L et al 

J Infect Dis.
2005 Mar 15;191(6):830-9.
Abstract
 
Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in
HIV-1-Infected Adults with Viral Suppression Receiving a Protease Inhibitor-Based
Regimen: A Randomized Trial.
Molina JM, Journot V, Morand-Joubert L et al  

J Infect Dis.
2005 Mar 15;191(6):830-9.
Abstract
 
A randomized study of emtricitabine and lamivudine in stably suppressed patients
with HIV.
Benson CA, van der Horst C, Lamarca A. et al 

AIDS.
2004 Nov 19;18(17):2269-2276.
Abstract
 
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-
naive patients: a randomized trial.
Saag MS, Cahn P, Raffi F, et al
JAMA. 2004 Jul 14;292(2):180-9.
Abstract

Prospective randomized trial of emtricitabine versus lamivudine short-term
monotherapy in human immunodeficiency virus-infected patients.
Rousseau FS, Wakeford C, Mommeja-Marin H, et al.
J Infect Dis. 2003 Dec 1;188(11):1652-8.
Abstract


Adverse Events
       

 
Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP.
Faltz M, Bergin H, Pilavachi E, et al
Cardiovasc Toxicol
. 2017 Jan 3.
Abstract

Hypersensitivity to lamivudine and emtricitabine.
L
oulergue P, Mir O.
Curr HIV Res. 2012 Sep 5
Abstract

Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected
Japanese patients.

Shirasaka T, Tadokoro T, Yamamoto Y,  et al
J Infect Chemother
. 2011 Mar 3.
Abstract

Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with
additional nucleoside reverse transcriptase inhibitors.

Venhoff N, Setzer B, Melkaoui K, Walker UA.  

Antivir Ther.
2007;12(7):1075-85.

Abstract

   
  Disorder in Clotting Pattern after Antiretroviral Treatment with Emtricitabine in an
HIV-Positive Haemophiliac Patient.

Liras A
 
Clin Drug Investig
. 2007;27(12):857-859.
Abstract

Therapeutic Strategies
       

 
Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention.
Clark MR, Peet MM, Davis S, et al

Pharmaceutics
. 2014 Dec 8;6(4):616-631.
Abstract

Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A case-control study.
Rossotti R, Moioli MC, Chianura L, et al
Scand J Infect Dis
. 2012 Jul 17.
Abstract

 


Emtricitabine Main Page Main New/Newsworthy  Home Page      

Emtricitabine Journal Citations